Let's Start with Peptides...

A few weeks ago, a 45-year-old member of my primary care practice texted me at 9pm. "What about peptides?"

She wasn't asking casually. She'd done her own research and was considering trying them at an area wellness clinic.

What Peptides Actually Are

Peptides are short chains of amino acids, the same building blocks that make up every protein in your body. Some occur naturally and play important roles in healing, inflammation, and hormone regulation. Using peptides as medicine is not a new or radical idea. Insulin is a peptide. Semaglutide, the molecule behind Ozempic and Wegovy, is a peptide. These are FDA-approved, well-studied, and backed by the kind of evidence that allows a physician to prescribe them with confidence.

But the peptides driving the current wellness conversation are in a very different place.

Where the Evidence Actually Stands

Let's look at BPC-157, the compound people ask about most. A 2025 review in the American Journal of Sports Medicine examined every published study on BPC-157: 544 articles going back three decades. After screening, 36 studies made the cut. Of those, 35 were animal studies. Only one involved human patients.¹

That one human study followed 12 people with chronic knee pain who received a BPC-157 injection. There was no control group, no blinding, and no standardized way of measuring outcomes or safety. Seven of the twelve reported improvement lasting more than six months.² Interesting, but it was seven individuals. Without a control group, we can't know whether the peptide made the difference or whether other factors were at play.

The animal data is genuinely interesting. In rodent models, BPC-157 appears to promote blood vessel growth, reduce inflammation, and support healing in tendons, muscles, ligaments, and bone.¹ But what works in animals doesn't always work in people. Rodents heal differently than we do. Their immune systems behave differently. That gap between animal research and human medicine is one that only well-designed clinical trials can bridge, and those trials haven't been done yet.

A 2025 review in Current Reviews in Musculoskeletal Medicine reached the same conclusion: despite growing use and popularity, the quality and depth of human data for BPC-157 remains far too thin to support clinical recommendations.³ A 2024 review in Pharmaceuticals described the clinical evidence as "limited but encouraging" and was clear that much more work is needed before real conclusions can be drawn.⁴

The only published safety data in humans comes from a 2025 pilot study of two healthy adults who received BPC-157 by IV. No side effects were observed, but with two participants, that tells us very little about how it might affect a broader population.⁵

The same gaps exist for TB-500, CJC-1295, ipamorelin, and most other peptides that were widely offered by wellness clinics in recent years. There are encouraging signals from the lab. There is almost no controlled human evidence.

The Regulatory Reality

In 2023, the FDA classified BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, and many other peptides as Category 2 bulk drug substances. That designation means the FDA considers them to carry potential safety concerns, and licensed pharmacies are no longer allowed to compound them for human use.⁶

The reasoning was straightforward: not enough human safety data, potential immune reactions, and concerns about impurities in compounds manufactured outside of regulated settings.⁶ The Department of Justice has prosecuted at least one compounding pharmacy for distributing these substances, resulting in forfeitures of more than $1.7 million.⁷

BPC-157 is also banned outright by WADA under its Non-Approved Substances category.⁸ The Department of Defense lists it as a prohibited supplement ingredient.⁹ Every major professional sports league in the U.S. enforces this ban.

These peptides are still available online, usually labeled "for research use only" with disclaimers that they are "not for human consumption." The reality is that most buyers are using them on themselves, often without physician guidance, without pharmaceutical-grade quality assurance, and without any way to verify what's actually in the vial. One 2025 review noted that between 12% and 58% of nutritional and performance supplements are contaminated with undisclosed substances.¹ Research-grade peptides are subject to even less oversight than supplements.

Why We Don't Offer These Peptides

Our decision not to offer Category 2 peptides isn't about being overly cautious. It's about being honest with our members.

At Valincare, we sort every recommendation into one of three categories: what is proven, what is promising, and what remains unknown. We tell our members which category they're looking at. When the evidence is uncertain, we say so. When we don't know, we say that too.

BPC-157 falls into the "promising" category. It may turn out to be a genuinely useful therapy. But promising and proven are separated by clinical trials, and right now, those trials don't exist. We aren't comfortable offering a substance that lacks adequate human safety and efficacy data, regardless of how much attention it's getting.

We also think this matters for the field as a whole. Longevity medicine is a serious, evolving discipline. When clinics offer unproven therapies without proper safety evidence, it makes it harder for the entire field to earn the trust it deserves. We want to be part of raising that standard.

What We Do Instead

This doesn't mean we stay away from the cutting edge. It means we approach it carefully, and with better tools.

When Valincare uses therapies for investigational purposes, we use FDA-approved medications with known safety profiles, prescribed off-label under direct physician supervision. That's a very different situation than using an unregulated compound with no human data.

Our rapamycin protocol uses sirolimus, a drug that has been FDA-approved for decades with well-established dosing, safety, and monitoring data from transplant medicine and oncology. Its use in aging biology is investigational, but the drug itself is thoroughly understood. We know how it behaves in the body. We know what to watch for. And we prescribe it through your licensed pharmacy at pharmaceutical grade, with structured lab monitoring throughout.

Our senolytic protocol uses dasatinib, an FDA-approved medication with extensive human safety data from its use in cancer treatment, combined with quercetin, a widely available plant compound with a well-characterized safety profile. The idea of using these drugs to clear damaged cells is still emerging. The drugs themselves are not.

That's the key distinction: when we work at the boundary of what medicine knows, we bring FDA-approved medications, pharmaceutical-grade quality, known pharmacology, and continuous physician oversight. We don't take shortcuts on the tools.

Not All Peptides Are the Same

Our position is not anti-peptide. It's anti-recklessness.

There is at least one peptide we view quite favorably: GHK-Cu, a naturally occurring copper-binding tripeptide found in human plasma. Unlike BPC-157, GHK-Cu has been studied in multiple randomized, controlled human trials, including double-blind studies for skin rejuvenation, wound healing after laser resurfacing, and treatment of diabetic ulcers.^{12 13} It has decades of published clinical use with a strong safety record.

There is also a critical regulatory distinction. In September 2023, the same month the FDA placed BPC-157 and others into Category 2, the agency placed topical GHK-Cu into Category 1, meaning it can be legally compounded by licensed pharmacies.¹⁴ Injectable GHK-Cu remains in Category 2, the same restricted status as BPC-157. The FDA drew a clear line between the two routes of administration, and we respect that line.

GHK-Cu is a natural component of your own blood. Its levels decline with age, from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60.¹² Topical application is essentially replenishing a compound your body already recognizes. The risk profile is fundamentally different from injecting a synthetic peptide that has never been through a controlled human safety trial.

This is what it looks like when the evidence, the regulatory pathway, and the biology align. We use GHK-Cu in our regenerative aesthetic protocols alongside PRP, PRF, exosomes, and growth factors because the data supports it and the law permits it. That's the standard every intervention should meet.